Human PD-1 / PDCD1 Protein, His Tag (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
PD1-H5221-100ug
$340.00
PD1-H5221-1mg (250ug X 4)
$2710.00
ETA of in-stock products:2 business days

Product Details

  • Synonym

    PDCD1, PD1, CD279, SLEB2

  • Source

    Human PD-1, His Tag (PD1-H5221) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # NP_005009.2).

    Predicted N-terminus: Leu 25

    Request for sequence
  • Molecular Characterization

    PD-1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 16.8 kDa. The protein migrates as 33-38 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    PD-1 SDS-PAGE

    Human PD-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    PD-1 SEC-MALS

    The purity of Human PD-1, His Tag (Cat. No. PD1-H5221) is more than 85% and the molecular weight of this protein is around 28-42 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     PD-1 ELISA

    Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL (100 μL/well) can bind Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5) with a linear range of 10-156 ng/mL (Routinely tested).

    Protocol
  •  PD-1 ELISA

    Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL (100 μL/well) can bind Nivolumab with a linear range of 0.1-3 ng/mL (Routinely tested).

    Protocol
  •  PD-1 ELISA

    Immobilized Cadonilimab at 1 μg/mL (100 μL/well) can bind Human PD-1, His Tag (Cat. No. PD1-H5221) with a linear range of 0.1-2 ng/mL (Routinely tested).

    Protocol
  •  PD-1 ELISA

    Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.99 ng/mL (Routinely tested).

    Protocol
  •  PD-1 ELISA

    Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) at 0.1 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 6.64 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     PD-1 SPR

    Opdivo (Nivolumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human PD-1, His Tag (Cat. No. PD1-H5221) with an affinity constant of 4.94 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     PD-1 BLI

    Loaded Human PD-1, His Tag (Cat. No. PD1-H5221) on HIS1K Biosensor, can bind Human PD-L1, Fc Tag (HPLC verified) (Cat. No. PD1-H5258) with an affinity constant of 38.9 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

    Protocol
  • PD-1 BATCH BLI
  •  PD-1 BLI

    Loaded Human PD-1, His Tag (Cat. No. PD1-H5221) on HIS1K Biosensor, can bind Human PD-L2, Fc Tag (HPLC verified) (Cat. No. PD2-H5251) with an affinity constant of 16.3 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

    Protocol
  •  PD-1 BLI

    Loaded Opdivo (Nivolumab) on ProteinA Biosensor, can bind Human PD-1, His Tag (Cat. No. PD1-H5221) with an affinity constant of 5.09 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  PD-1 BLI

    Loaded Human PD-L1, Mouse IgG1 Fc Tag, low endotoxin (HPLC-verified) (Cat. No. PD1-H52A3) on AMC Biosensor, can bind Human Human PD-1, His Tag (Cat. No. PD1-H5221) with an affinity constant of 2.1 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Recent Advances

 
Drug Development Progress
  • English Name:

    Programmed cell death protein 1

  • Category:

  • Approved Drugs:

    20 Details

  • Drugs in Clinical Trials:

    167 Details

  • Highest Development Stage:

    Phase 3 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background